No. 20-1119

Amarin Pharma, Inc., et al. v. Hikma Pharmaceuticals USA Inc., et al.

Lower Court: Federal Circuit
Docketed: 2021-02-16
Status: Denied
Type: Paid
Amici (3)Response RequestedResponse WaivedRelisted (2) Experienced Counsel
Tags: 35-usc-103 graham-factors graham-v-john-deere hindsight-bias innovation innovation-protection nonobviousness-indicia objective-indicia obviousness-standard patent patent-law
Key Terms:
Environmental Patent Privacy JusticiabilityDoctri
Latest Conference: 2021-06-17 (distributed 2 times)
Question Presented (AI Summary)

Whether a court must consider objective indicia of nonobviousness together with the other factors bearing on an obviousness challenge before making any obviousness determination

Question Presented (OCR Extract)

QUESTION PRESENTED In Graham v. John Deere Co. of Kansas City, 383 USS. 1 (1966), this Court established four factors that a court must consider in determining whether a patent is obvious and therefore unpatentable under 35 U.S.C. § 103. Three of those factors relate to technical differences between the invention and the prior art. The fourth factor concerns objective facts indicating that the field of art did not treat the claimed invention as obvious. These objective indicia include long-felt but unresolved needs ultimately addressed by the invention, failure of others to make the invention, and commercial success of products embodying the invention. This Court has made clear that objective indicia must be considered along with the other factors before concluding that any invention is obvious, so that real world indicators—which are often the strongest evidence of nonobviousness—may guard against the risk that patents will incorrectly appear obvious in hindsight. The Federal Circuit has improperly relegated objective indicia of nonobviousness to a secondary role. Under the Federal Circuit’s framework, a court first considers only the three technical Graham factors and reaches a conclusion of “prima facie” obviousness. Only then does the court consider objective indicia, merely as a basis for rebutting a conclusion already reached. The result is over-invalidation of patents through hindsight bias and the suppression of innovation. The question presented is: Whether a court must consider objective indicia of nonobviousness together with the other factors bearing on an obviousness challenge before making any obviousness determination. @

Docket Entries

2021-06-21
Petition DENIED.
2021-06-01
DISTRIBUTED for Conference of 6/17/2021.
2021-06-01
Reply of petitioners Amarin Pharma, Inc., et al. filed. (Distributed)
2021-05-18
Brief of respondent Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals International Limited in opposition filed.
2021-04-07
Response to motion from petitioner Amarin Pharma, Inc., et al. filed.
2021-04-07
Motion to extend the time to file a response is granted in part and the time is extended to and including May 18, 2021.
2021-04-06
Motion to extend the time to file a response from April 29, 2021 to June 14, 2021, submitted to The Clerk.
2021-03-30
Response Requested. (Due April 29, 2021)
2021-03-24
DISTRIBUTED for Conference of 4/16/2021.
2021-03-04
Brief amicus curiae of Aimed Alliance filed.
2021-03-01
Brief amicus curiae of LiquidPower Specialty Products Inc. filed.
2021-02-24
Waiver of right of respondents Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. to respond filed.
2021-02-23
Waiver of right of respondent Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals International Limited to respond filed.
2021-02-23
Brief amicus curiae of US Inventor Inc. filed.
2021-02-11
Petition for a writ of certiorari filed. (Response due March 18, 2021)

Attorneys

Aimed Alliance
Ashley C. ParrishKing & Spalding, Amicus
Amarin Pharma, Inc., et al.
Seth P. WaxmanWilmer Cutler Pickering Hale and Dorr LLP, Petitioner
Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.
Constance S. HuttnerWindels Marx Lane & Mittendorf, LLP, Respondent
Hikma Pharmaceuticals USA Inc., Hikma Pharmaceuticals International Limited
Charles Bennett KleinWinston & Strawn LLP, Respondent
LiquidPower Specialty Products Inc.
Zachary D. TrippWeil, Gotshal & Manges LLP, Amicus
US Inventor Inc.
Robert P. GreenspoonFlachsbart & Greenspoon, LLC, Amicus